.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Redcliffe Labs recently announced the appointment of Dr. Sonal Saxena as Director of Lab Operations. This strategic move aims to bolster Redcliffe Labs diagnostic services by focusing on quality and preventive care. Consequently, Dr. Saxena will manage the company's extensive nationwide network of laboratories. Furthermore, she brings over 25 years of expertise in pathology and clinical diagnostics to her new role.
Dr. Saxena previously worked with prestigious organizations like Dr. Lal Path Labs and Apollo Clinic. Because she has an extensive background in reference lab establishment, she is well-suited for this leadership position. In addition, she serves as a trained ISO 15189 assessor. Therefore, her expertise will help the company maintain high technical standards and operational excellence across all centers. Moreover, she will focus on enhancing technical processes and quality systems to meet global benchmarks.
The diagnostic industry in India is evolving toward a proactive healthcare model. For this reason, Redcliffe Labs is prioritizing accessibility alongside reliability. Dr. Saxena aims to enhance laboratory processes to support early disease detection. Additionally, she has played a key role in securing NABL and CAP accreditations in earlier assignments. Finally, these improvements will lead to better health outcomes for patients across the country through consistent and accurate testing protocols.
Q1: Who is the new Director of Lab Operations at Redcliffe Labs?
Dr. Sonal Saxena has been appointed as the Director of Lab Operations at Redcliffe Labs, bringing over 25 years of experience in pathology and medicine.
Q2: What are the primary goals of Dr. Saxena's appointment?
The primary goals include strengthening diagnostic quality, expanding preventive healthcare capabilities, and enhancing accreditation standards across the nationwide network.
Q3: Which accreditations will Dr. Saxena focus on at Redcliffe Labs?
As a trained ISO 15189 assessor, she will focus on maintaining and securing NABL, CAP, and ISO accreditations to ensure high-quality laboratory standards.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Redcliffe Labs appoints Dr. Sonal Saxena as Director – Lab Operations to drive diagnostic quality, accreditation standards, and preventive healthcare expans...
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
